[6-K] ICICI Bank Limited Current Report (Foreign Issuer)
DexCom, Inc. (DXCM) Form 144 filing discloses a proposed sale of 1,466 common shares by shareholder Sadie Stern through Morgan Stanley Smith Barney. The shares, valued at $130,459, are expected to be sold on or about 28 Jul 2025 on the NASDAQ. They represent roughly 0.0004 % of DexCom’s 392.1 million shares outstanding, implying minimal market impact.
The shares were acquired as restricted stock on 19 Nov 2023. In the last three months, the same holder completed four sales totaling 7,650 shares for $651,016 in gross proceeds, indicating an ongoing liquidation pattern. No other insiders or financial metrics are disclosed.
The filer affirms awareness of no undisclosed adverse information and notes potential reliance on a Rule 10b5-1 trading plan. Aside from insider-sale data, the filing contains no operational or earnings updates.
DexCom, Inc. (DXCM) Comunicazione Form 144 rivela una proposta di vendita di 1.466 azioni ordinarie da parte dell'azionista Sadie Stern tramite Morgan Stanley Smith Barney. Le azioni, valutate 130.459 $, dovrebbero essere vendute intorno al 28 luglio 2025 sul NASDAQ. Rappresentano circa lo 0,0004 % delle 392,1 milioni di azioni in circolazione di DexCom, indicando un impatto di mercato minimo.
Le azioni sono state acquisite come azioni vincolate il 19 novembre 2023. Negli ultimi tre mesi, lo stesso azionista ha effettuato quattro vendite per un totale di 7.650 azioni, con un ricavo lordo di 651.016 $, evidenziando un andamento di liquidazione in corso. Non sono divulgati altri insider o dati finanziari.
Il dichiarante conferma di non essere a conoscenza di informazioni negative non divulgate e segnala un possibile ricorso a un piano di trading conforme alla Regola 10b5-1. Oltre ai dati sulle vendite degli insider, la comunicazione non contiene aggiornamenti operativi o sugli utili.
DexCom, Inc. (DXCM) Presentación del Formulario 144 revela una propuesta de venta de 1,466 acciones comunes por parte de la accionista Sadie Stern a través de Morgan Stanley Smith Barney. Las acciones, valoradas en 130,459 $, se espera que se vendan alrededor del 28 de julio de 2025 en el NASDAQ. Representan aproximadamente el 0.0004 % de las 392.1 millones de acciones en circulación de DexCom, lo que implica un impacto mínimo en el mercado.
Las acciones fueron adquiridas como acciones restringidas el 19 de noviembre de 2023. En los últimos tres meses, la misma titular completó cuatro ventas por un total de 7,650 acciones por 651,016 $ en ingresos brutos, indicando un patrón de liquidación en curso. No se revelan otros insiders ni métricas financieras.
El declarante afirma no tener conocimiento de información adversa no divulgada y señala una posible dependencia de un plan de negociación conforme a la Regla 10b5-1. Aparte de los datos de ventas de insiders, la presentación no contiene actualizaciones operativas o de ganancias.
DexCom, Inc. (DXCM) Form 144 제출은 Morgan Stanley Smith Barney를 통해 주주 Sadie Stern이 1,466 보통주를 매도할 예정임을 공개합니다. 해당 주식은 130,459 달러 가치로, 2025년 7월 28일경 NASDAQ에서 매도될 예정입니다. 이는 DexCom의 3억 9,210만 주 중 약 0.0004%에 해당하여 시장에 미치는 영향은 미미할 것으로 보입니다.
해당 주식은 2023년 11월 19일 제한 주식으로 취득되었습니다. 지난 3개월 동안 동일 주주는 총 7,650주를 매도하여 총 651,016 달러의 총수익을 올렸으며, 이는 지속적인 청산 패턴을 나타냅니다. 다른 내부자나 재무 지표는 공개되지 않았습니다.
제출자는 미공개 불리한 정보가 없음을 확인하며, Rule 10b5-1 거래 계획에 의존할 가능성이 있음을 언급합니다. 내부자 매도 데이터 외에는 운영이나 수익에 관한 업데이트는 포함되어 있지 않습니다.
DexCom, Inc. (DXCM) Déclaration Formulaire 144 révèle une proposition de vente de 1 466 actions ordinaires par l'actionnaire Sadie Stern via Morgan Stanley Smith Barney. Les actions, évaluées à 130 459 $, devraient être vendues vers le 28 juillet 2025 sur le NASDAQ. Elles représentent environ 0,0004 % des 392,1 millions d'actions en circulation de DexCom, ce qui implique un impact minimal sur le marché.
Les actions ont été acquises en tant qu'actions restreintes le 19 novembre 2023. Au cours des trois derniers mois, le même détenteur a réalisé quatre ventes totalisant 7 650 actions pour un produit brut de 651 016 $, indiquant un schéma de liquidation en cours. Aucun autre initié ni indicateur financier n'est divulgué.
Le déclarant affirme ne pas avoir connaissance d'informations défavorables non divulguées et note une possible dépendance à un plan de trading conforme à la règle 10b5-1. En dehors des données sur les ventes d'initiés, la déclaration ne contient aucune mise à jour opérationnelle ou sur les résultats.
DexCom, Inc. (DXCM) Form 144 Meldung offenbart einen geplanten Verkauf von 1.466 Stammaktien durch Aktionärin Sadie Stern über Morgan Stanley Smith Barney. Die Aktien im Wert von 130.459 $ sollen etwa am 28. Juli 2025 an der NASDAQ verkauft werden. Sie entsprechen etwa 0,0004 % der 392,1 Millionen ausstehenden Aktien von DexCom, was auf eine minimale Marktauswirkung hinweist.
Die Aktien wurden als eingeschränkte Aktien am 19. November 2023 erworben. In den letzten drei Monaten hat derselbe Inhaber vier Verkäufe mit insgesamt 7.650 Aktien für 651.016 $ Bruttoerlös abgeschlossen, was auf ein fortlaufendes Liquidationsmuster hindeutet. Weitere Insider oder finanzielle Kennzahlen werden nicht offengelegt.
Der Einreicher bestätigt, dass ihm keine nicht offengelegten nachteiligen Informationen bekannt sind, und verweist auf eine mögliche Nutzung eines Handelsplans gemäß Regel 10b5-1. Abgesehen von den Insider-Verkaufsdaten enthält die Meldung keine operativen oder Gewinnaktualisierungen.
- Sale equals only 0.0004 % of shares outstanding, implying negligible dilution or market impact.
- Timely Rule 144 disclosure enhances transparency around insider trading activity.
- 7,650 shares already sold in the last three months may signal continued insider off-loading.
- No accompanying operational or financial update, leaving investors without context for the sales.
Insights
TL;DR: Minor DexCom insider sale (1,466 shares) is immaterial to float; pattern of recent sales worth $651k may draw scrutiny but lacks major impact.
The 1,466-share Form 144 equals only 0.0004 % of outstanding stock, so price pressure should be negligible. However, the filer has already liquidated 7,650 shares over the past quarter, signalling personal diversification or profit-taking. Because no company fundamentals are included, the filing does not alter the investment thesis. Overall impact: neutral.
TL;DR: Filing shows compliant disclosure; continued sales could raise perception questions but remain within Rule 144 limits.
Timely Form 144 submission demonstrates adherence to SEC rules, giving markets visibility into insider activity. The fractional size versus float limits governance concern. Still, investors may monitor if sales persist or expand, as sustained insider selling can affect sentiment even when legally permitted.
DexCom, Inc. (DXCM) Comunicazione Form 144 rivela una proposta di vendita di 1.466 azioni ordinarie da parte dell'azionista Sadie Stern tramite Morgan Stanley Smith Barney. Le azioni, valutate 130.459 $, dovrebbero essere vendute intorno al 28 luglio 2025 sul NASDAQ. Rappresentano circa lo 0,0004 % delle 392,1 milioni di azioni in circolazione di DexCom, indicando un impatto di mercato minimo.
Le azioni sono state acquisite come azioni vincolate il 19 novembre 2023. Negli ultimi tre mesi, lo stesso azionista ha effettuato quattro vendite per un totale di 7.650 azioni, con un ricavo lordo di 651.016 $, evidenziando un andamento di liquidazione in corso. Non sono divulgati altri insider o dati finanziari.
Il dichiarante conferma di non essere a conoscenza di informazioni negative non divulgate e segnala un possibile ricorso a un piano di trading conforme alla Regola 10b5-1. Oltre ai dati sulle vendite degli insider, la comunicazione non contiene aggiornamenti operativi o sugli utili.
DexCom, Inc. (DXCM) Presentación del Formulario 144 revela una propuesta de venta de 1,466 acciones comunes por parte de la accionista Sadie Stern a través de Morgan Stanley Smith Barney. Las acciones, valoradas en 130,459 $, se espera que se vendan alrededor del 28 de julio de 2025 en el NASDAQ. Representan aproximadamente el 0.0004 % de las 392.1 millones de acciones en circulación de DexCom, lo que implica un impacto mínimo en el mercado.
Las acciones fueron adquiridas como acciones restringidas el 19 de noviembre de 2023. En los últimos tres meses, la misma titular completó cuatro ventas por un total de 7,650 acciones por 651,016 $ en ingresos brutos, indicando un patrón de liquidación en curso. No se revelan otros insiders ni métricas financieras.
El declarante afirma no tener conocimiento de información adversa no divulgada y señala una posible dependencia de un plan de negociación conforme a la Regla 10b5-1. Aparte de los datos de ventas de insiders, la presentación no contiene actualizaciones operativas o de ganancias.
DexCom, Inc. (DXCM) Form 144 제출은 Morgan Stanley Smith Barney를 통해 주주 Sadie Stern이 1,466 보통주를 매도할 예정임을 공개합니다. 해당 주식은 130,459 달러 가치로, 2025년 7월 28일경 NASDAQ에서 매도될 예정입니다. 이는 DexCom의 3억 9,210만 주 중 약 0.0004%에 해당하여 시장에 미치는 영향은 미미할 것으로 보입니다.
해당 주식은 2023년 11월 19일 제한 주식으로 취득되었습니다. 지난 3개월 동안 동일 주주는 총 7,650주를 매도하여 총 651,016 달러의 총수익을 올렸으며, 이는 지속적인 청산 패턴을 나타냅니다. 다른 내부자나 재무 지표는 공개되지 않았습니다.
제출자는 미공개 불리한 정보가 없음을 확인하며, Rule 10b5-1 거래 계획에 의존할 가능성이 있음을 언급합니다. 내부자 매도 데이터 외에는 운영이나 수익에 관한 업데이트는 포함되어 있지 않습니다.
DexCom, Inc. (DXCM) Déclaration Formulaire 144 révèle une proposition de vente de 1 466 actions ordinaires par l'actionnaire Sadie Stern via Morgan Stanley Smith Barney. Les actions, évaluées à 130 459 $, devraient être vendues vers le 28 juillet 2025 sur le NASDAQ. Elles représentent environ 0,0004 % des 392,1 millions d'actions en circulation de DexCom, ce qui implique un impact minimal sur le marché.
Les actions ont été acquises en tant qu'actions restreintes le 19 novembre 2023. Au cours des trois derniers mois, le même détenteur a réalisé quatre ventes totalisant 7 650 actions pour un produit brut de 651 016 $, indiquant un schéma de liquidation en cours. Aucun autre initié ni indicateur financier n'est divulgué.
Le déclarant affirme ne pas avoir connaissance d'informations défavorables non divulguées et note une possible dépendance à un plan de trading conforme à la règle 10b5-1. En dehors des données sur les ventes d'initiés, la déclaration ne contient aucune mise à jour opérationnelle ou sur les résultats.
DexCom, Inc. (DXCM) Form 144 Meldung offenbart einen geplanten Verkauf von 1.466 Stammaktien durch Aktionärin Sadie Stern über Morgan Stanley Smith Barney. Die Aktien im Wert von 130.459 $ sollen etwa am 28. Juli 2025 an der NASDAQ verkauft werden. Sie entsprechen etwa 0,0004 % der 392,1 Millionen ausstehenden Aktien von DexCom, was auf eine minimale Marktauswirkung hinweist.
Die Aktien wurden als eingeschränkte Aktien am 19. November 2023 erworben. In den letzten drei Monaten hat derselbe Inhaber vier Verkäufe mit insgesamt 7.650 Aktien für 651.016 $ Bruttoerlös abgeschlossen, was auf ein fortlaufendes Liquidationsmuster hindeutet. Weitere Insider oder finanzielle Kennzahlen werden nicht offengelegt.
Der Einreicher bestätigt, dass ihm keine nicht offengelegten nachteiligen Informationen bekannt sind, und verweist auf eine mögliche Nutzung eines Handelsplans gemäß Regel 10b5-1. Abgesehen von den Insider-Verkaufsdaten enthält die Meldung keine operativen oder Gewinnaktualisierungen.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a -16 OR
15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of July 2025
Commission File Number: 001-15002
ICICI Bank Limited
(Translation of registrant’s name into English)
ICICI Bank Towers,
Bandra-Kurla Complex
Mumbai, India 400 051
(Address of principal executive office)
Indicate by check mark whether the registrant files
or will file
annual reports under cover Form 20-F or Form 40-F.
| Form 20-F X | Form 40-F |
Table of Contents
Items:
| 1. | Form 6K dated July 25, 2025 |
| 2. | Filing of Form 20F dated July 25, 2025 |
July 25, 2025
The United States
Securities and Exchange Commission
Washington D.C. 20549
United States of America
Attn.: Filing Desk
Dear Sir/Madam,
| Subject: | Filing of Annual Report in Form 20-F for the year ended March 31, 2025 |
IBN
ICICI Bank Limited (the ‘Company’) Report on Form 6-K
On behalf of the Company, I am enclosing for filing, signed copy of the Company’s Report on Form 6-K dated July 25, 2025 in connection with filing of Annual Report in Form 20-F with Securities and Exchange Commission for the year ended March 31, 2025. We enclose herewith the details of Form 20-F as forwarded to Indian Stock Exchanges in this regard.
This is for your reference and records.
Yours sincerely,
For ICICI Bank Limited
/s/ Vivek Ranjan
Vivek Ranjan
Associate Leadership Team
Encl.: As above
 |
ICICI Bank Limited L65190GJ1994PLC021012 ICICI Bank Towers Bandra Kurla Complex Mumbai 400 051 |
Filing of Form 20-F
ICICI Bank Limited (NYSE: IBN) filed its annual report in Form 20-F for the year ended March 31, 2025 (FY2025) on July 25, 2025, as required by United States securities regulations. The Form 20-F annual report includes the Bank’s consolidated financial statements under Indian GAAP and a reconciliation of consolidated profit after tax and net worth under Indian GAAP to net income and stockholders’ equity respectively, under U.S. GAAP, approved by the Audit Committee of the Board.
There are differences in the basis of accounting between U.S. GAAP and Indian GAAP primarily relating to allowance for loan losses, business combinations, consolidation, valuation of securities and derivatives, amortization of fees and costs, securitization, income taxes and fixed assets.
The consolidated profit after tax under Indian GAAP increased from Rs. 44,256 crore (US$ 5,180 million) in FY2024 to Rs. 51,029 crore (US$ 5,973 million) in FY2025. The consolidated net income under U.S. GAAP in FY2025 was Rs. 51,354 crore (US$ 6,011 million) compared to Rs. 61,376 crore (US$ 7,184 million) in FY2024.
Stockholders’ equity as per U.S. GAAP was Rs. 365,480 crore (US$ 42.8 billion) compared to the consolidated net worth as per Indian GAAP of Rs. 313,906 crore (US$ 36.7 billion) at March 31, 2025. The reconciliation of consolidated profit after tax and net worth under Indian GAAP to net income and stockholders’ equity under U.S. GAAP is explained in note 21 of the consolidated financial statements of the Bank in Form 20-F.
Pursuant to its issuance and listing of securities in the United States under registration statements filed with the Securities and Exchange Commission, ICICI Bank files annual report in Form 20-F with the SEC as required by U.S. securities laws and regulations. ICICI Bank in its annual report in Form 20-F includes consolidated financial statements under Indian GAAP, with a reconciliation of profit after tax and net worth under Indian GAAP to net income and stockholders' equity respectively, under U.S. GAAP and a description of differences between Indian GAAP and U.S. GAAP.
Copies of the Form 20-F are available from the United States Securities and Exchange Commission (SEC) website www.sec.gov or via a direct link to the SEC website at "About Us/Annual reports" page of ICICI Bank's website:
(https://www.sec.gov/Archives/edgar/data/1103838/000095010325009269/dp231278_20f.htm)
|
ICICI Bank Limited L65190GJ1994PLC021012 ICICI Bank Towers Bandra Kurla Complex Mumbai 400 051 |
Shareholders may obtain a copy of the complete audited financial statements free of charge by writing to Company Secretary, ICICI Bank Limited, ICICI Bank Towers, Bandra Kurla Complex, Mumbai 400051 or sending an e-mail to companysecretary@icicibank.com, with details of their shareholding and mailing address.
For further press queries please contact Sujit Ganguli / Kausik Datta at sujit.ganguli@icicibank.com / datta.kausik@icicibank.com or corporate.communications@icicibank.com.
For investor queries please contact Abhinek Bhargava / Nitesh Kalantri at abhinek.bhargava@icicibank.com / nitesh.kalantri@icicibank.com or ir@icicibank.com.
1 crore = 10 million
US$ amounts represent convenience translations at US$1= Rs. 85.43
| Mumbai | For ICICI Bank Limited |
| July 25, 2025 | |
| /s/ Anindya Banerjee | |
| Anindya Banerjee | |
| Group Chief Financial Officer |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
For ICICI Bank Limited | ||||
| Date |
: July 25, 2025 |
By: | /s/ Vivek Ranjan | |
| Name: | Vivek Ranjan | |||
| Title: | Associate Leadership Team | |||
FAQ
How many DexCom (DXCM) shares are proposed for sale in this Form 144?
Who is the selling shareholder in the July 2025 DexCom Form 144?
What percentage of DexCom’s outstanding shares does the 1,466-share sale represent?
How many DexCom shares has the filer sold in the past three months?
When were the shares to be sold originally acquired?
